PMID- 33065780
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Sep
TI  - Effect of evolocumab on the progression and stability of atherosclerotic plaques 
      as evaluated by grayscale and iMAP-IVUS.
PG  - 3078-3088
LID - 10.21037/apm-20-690 [doi]
AB  - BACKGROUND: Evolocumab inhibits the proprotein convertase subtilisin/kexin type 9 
      protein and is a potent cholesterol-lowering drug. However, the relationship 
      between evolocumab and inflammation, and the effects of evolocumab on the 
      stability of atherosclerotic plaques remain unknown. METHODS: Twenty-seven 
      purebred New Zealand rabbits were fed with an atherogenic diet for 2 weeks. The 
      abdominal aortic endothelium was balloon-injured. The rabbits were divided into 
      the atorvastatin (2 mg/kg/day; Ato), evolocumab (7 mg/kg/2 weeks, Evo) and 
      control groups. Intravascular ultrasound (IVUS) images of the abdominal artery 
      were analyzed at 10 and 18 weeks. Additionally, the serum levels of the 
      biomarkers were measured at baseline, and at 10 and 18 weeks. RESULTS: The serum 
      levels of triglycerides, total cholesterol, low-density lipoprotein cholesterol 
      (LDL-C), and monocyte chemoattractant protein-1 (MCP-1) increased after 10 weeks 
      of administration of the proatherosclerotic diet, while the levels of 
      high-density lipoprotein cholesterol (HDL-C) and transforming growth factor-beta 
      (TGF-beta) decreased. The reduction in the serum levels of triglycerides, total 
      cholesterol, LDL-C, MCP-1, TGF-beta, and toll-like receptor 4 (TLR4) following 
      treatment with evolocumab was higher than that of atorvastatin. Both evolocumab 
      and atorvastatin reduced the percent atheroma volume. Evolocumab increased the 
      fibrotic% and decreased the necrotic%. Correlation analysis revealed that the 
      levels of triglycerides, total cholesterol, LDL-C, MCP-1, TGF-beta, and TLR4 were 
      negatively correlated with the fibrotic%, but were positively correlated with the 
      necrotic%. Multivariate linear regression analysis revealed that treatment with 
      atorvastatin, and especially evolocumab, was a consistent predictor of the 
      percent atheroma volume, and fibrotic and necrotic composition. CONCLUSIONS: 
      Proprotein convertase subtilisin/kexin type 9 regulates the serum levels of lipid 
      and cholesterol may via inflammatory pathways. The results also indicate that 
      evolocumab is more potent than atorvastatin in suppressing the progression and 
      stability of atherosclerotic plaque in rabbits.
FAU - Kong, Qingzan
AU  - Kong Q
AD  - Department of Cardiology, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Liu, Miao
AU  - Liu M
AD  - Department of Cardiology, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Li, Yueyan
AU  - Li Y
AD  - Department of Cardiology, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Zhu, Qing
AU  - Zhu Q
AD  - Department of Pathology, Blood Center of Shandong Province, Jinan, China.
FAU - Su, Guohai
AU  - Su G
AD  - Department of Cardiology, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China. guohaisu1234@163.com.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Anticholesteremic Agents)
RN  - LKC0U3A8NJ (evolocumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Anticholesteremic Agents/therapeutic use
MH  - *Plaque, Atherosclerotic
MH  - Rabbits
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Atherosclerosis
OT  - evolocumab
OT  - iMAP
OT  - intravascular ultrasound (IVUS)
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 01:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/10/17 01:00 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.21037/apm-20-690 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2020 Sep;9(5):3078-3088. doi: 10.21037/apm-20-690.